=> d his

(FILE 'HOME' ENTERED AT 17:05:57 ON 23 NOV 1998)

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR,
AQUASCI, BIOBUSINESS, BIOSIS, BIOTECHABS, BIOTECHDS, CABA,
CANCERLIT, CAPLUS, CEABA, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL,
...' ENTERED AT 17:06:30 ON 23 NOV 1998

```
           E CHU H/IN
           SEA E3-E12
          ---------
           0*  FILE ADISALERTS
           0*  FILE ADISINSIGHT
           0*  FILE AGRICOLA
           0*  FILE AIDSLINE
           0*  FILE ANABSTR
           0*  FILE AQUASCI
           0*  FILE BIOBUSINESS
           0*  FILE BIOSIS
           5   FILE BIOTECHABS
           5   FILE BIOTECHDS
           0*  FILE CANCERLIT
           1   FILE CAPLUS
           0*  FILE CEABA
           0*  FILE CEN
           0*  FILE CIN
           0*  FILE CONFSCI
           7   FILE DDFB
           0*  FILE DDFU
          42   FILE DGENE
           7   FILE DRUGB
           0*  FILE DRUGLAUNCH
           0*  FILE DRUGMONOG2
           0*  FILE DRUGNL
           0*  FILE DRUGU
           0*  FILE EMBAL
           0*  FILE EMBASE
           1   FILE FSTA
           0*  FILE GENBANK
           0*  FILE HEALSAFE
           0*  FILE KOSMET
           0*  FILE LIFESCI
           0*  FILE MEDLINE
           0*  FILE NIOSHTIC
           0*  FILE NTIS
           0*  FILE OCEAN
           0*  FILE PHAR
           0*  FILE PHIC
           0*  FILE PHIN
           0*  FILE PROMT
           0*  FILE SCISEARCH
           0*  FILE TOXLINE
           0*  FILE TOXLIT
          67   FILE WPIDS
          67   FILE WPINDEX
           5   FILE APIPAT
          60   FILE DPCI
```

```
                7   FILE EUROPATFULL
                3   FILE INPADOC
                1   FILE PATDPA
                1   FILE PATOSDE
               38   FILE PATOSEP
               23   FILE PATOSWO
                2   FILE PIRA
                6   FILE RAPRA
                3   FILE TULSA
                3   FILE TULSA2
L1               QUE ("CHU H"/IN OR "CHU H C"/IN OR "CHU H D"/IN OR "CHU H
                ---------
                 SEA L1 AND STREPTOCOCCUS EQUI
                ---------
                0*  FILE ADISALERTS
                0*  FILE ADISINSIGHT
                0*  FILE AGRICOLA
                0*  FILE AIDSLINE
                0*  FILE ANABSTR
                0*  FILE AQUASCI
                0*  FILE BIOBUSINESS
                0*  FILE BIOSIS
                0*  FILE CANCERLIT
                0*  FILE CEABA
                0*  FILE CEN
                0*  FILE CIN
                0*  FILE CONFSCI
                0*  FILE DDFU
                0*  FILE DRUGLAUNCH
                0*  FILE DRUGMONOG2
                0*  FILE DRUGNL
                0*  FILE DRUGU
                0*  FILE EMBAL
                0*  FILE EMBASE
                0*  FILE GENBANK
                0*  FILE HEALSAFE
                0*  FILE KOSMET
                0*  FILE LIFESCI
                0*  FILE MEDLINE
                0*  FILE NIOSHTIC
                0*  FILE NTIS
                0*  FILE OCEAN
                0*  FILE PHAR
                0*  FILE PHIC
                0*  FILE PHIN
                0*  FILE PROMT
                0*  FILE SCISEARCH
                0*  FILE TOXLINE
                0*  FILE TOXLIT
L2               QUE L1 AND STREPTOCOCCUS EQUI
                ---------
```

```
=> s attenuatedstreptococcus equi
<------User Break------>
u
=> s attenuated streptococcus equi

  25 FILES SEARCHED...
         1   FILE IFIPAT
  40 FILES SEARCHED...
         1   FILE USPATFULL
         1   FILE EUROPATFULL
  53 FILES SEARCHED...

   3 FILES HAVE ONE OR MORE ANSWERS,    65 FILES SEARCHED IN STNINDEX

L1   QUE ATTENUATED STREPTOCOCCUS EQUI
```

```
=> d his

     (FILE 'HOME' ENTERED AT 15:49:38 ON 23 NOV 1998)

     INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR,
     AQUASCI, BIOBUSINESS, BIOSIS, BIOTECHABS, BIOTECHDS, CABA,
     CANCERLIT, CAPLUS, CEABA, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
     DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL,
     ...' ENTERED AT 15:49:52 ON 23 NOV 1998
               SEA STREPTOCOCCUS EQUI
              ---------
            116   FILE AGRICOLA
               SEA ATTENUATEDSTREPTOCOCCUS EQUI
              ---------
               SEA ATTENUATED STREPTOCOCCUS EQUI
              ---------
               1   FILE IFIPAT
               1   FILE USPATFULL
               1   FILE EUROPATFULL
L1             QUE ATTENUATED STREPTOCOCCUS EQUI
              ---------
               SEA STREPTOCOCCUS EQUI
              ---------
            116   FILE AGRICOLA
              1   FILE AIDSLINE
              1   FILE AQUASCI
             12   FILE BIOBUSINESS
            184   FILE BIOSIS
             56   FILE BIOTECHABS
             56   FILE BIOTECHDS
            276   FILE CABA
              2   FILE CANCERLIT
            110   FILE CAPLUS
              4   FILE CEABA
              1   FILE CIN
              3   FILE CONFSCI
             10   FILE DGENE
              1   FILE DRUGU
             90   FILE EMBASE
             36   FILE GENBANK
             18   FILE IFIPAT
             18   FILE JICST-EPLUS
             71   FILE LIFESCI
            133   FILE MEDLINE
              1   FILE PHAR
             14   FILE PHIN
              1   FILE PROMT
            100   FILE SCISEARCH
             10   FILE TOXLINE
             17   FILE TOXLIT
             54   FILE USPATFULL
             36   FILE WPIDS
             36   FILE WPINDEX
             14   FILE DPCI
              8   FILE EUROPATFULL
             49   FILE INPADOC
             16   FILE JAPIO
              4   FILE PATDPA
```

```
                2   FIL[redacted]ATOSDE
                5   FIL[redacted]PATOSEP
                2   FILE PATOSWO
L2               QUE STREPTOCOCCUS EQUI
                ---------

     FILE 'CABA, BIOSIS, MEDLINE, AGRICOLA, CAPLUS, SCISEARCH, EMBASE,
     LIFESCI, BIOTECHDS, USPATFULL, INPADOC, GENBANK, WPIDS, IFIPAT,
     JICST-EPLUS, TOXLIT, JAPIO, PHIN, DPCI, BIOBUSINESS, DGENE,
     TOXLINE, EUROPATFULL, PATOSEP, CEABA, PATDPA, CONFSCI, CANCERLIT,
     ...' ENTERED AT 15:54:43 ON 23 NOV 1998
L3          1476 S STREPTOCOCCUS EQUI
L4           828 DUP REM L3 (648 DUPLICATES REMOVED)
L5             2 S L4(10A)ATTENUATED
L6             0 S L5 AND ADJUVANT
L7             0 S L5 AND SAPONIN
L8           128 S L4 AND VACCINE
L9             2 S 8L AND SAPONIN
L10            2 S L8 AND SAPONIN

=> log y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

Pat. No. 4,944,943

The . . . methyl salicylate the preferred range is between 1 and 4 weight percent. Finally, the formulation may contain a recognized vaccine **adjuvant** such as aluminum hydroxide gel or those taught in U.S. Pat. No. 3,919,411, preferably at levels between about 5 and. . . for the former type and levels between about 5 and 20% being preferred for the latter type. An especially preferred **adjuvant** is based on the polyacrylic acid cross linked with polyallyl sucrose sold as Carbopol 934P combined with polyoxyethylene sorbitan mono-oleate. . .

> d his

(FILE 'USPAT' ENTERED AT 15:40:11 ON 23 NOV 1998)
L1 54 S STREPTOCOCCUS EQUI
L2 1 S L1 AND SAPONIN
L3 23 S L1 AND VACCINE
L4 0 S ATTENUATED STREPTOCOCCU SEQUI
L5 1 S ATTENUATED STREPTOCOCUS EQUI
L6 0 S L5 AND ADJUVANT
L7 0 S L5 AND INERFERON
L8 1 S L5
L9 0 S L5 AND SAPONIN

=> s l8

31405 ATTENUATED
6273 STREPTOCOCCUS
8108 EQUI
L10 1 ATTENUATED STREPTOCOCUS EQUI
(ATTENUATED(W)STREPTOCOCCUS(W)EQUI)

=> d 1 kwic

US PAT NO: 4,788,059 [IMAGE AVAILABLE] L10: 1 of 1

SUMMARY:

BSUM(10)

It . . . invention to provide . . hod of immunizing equines against virulent strains of Streptococcus . by inoculating the equine with an **attenuated Streptococcus equi** .

CLAIMS:

CLMS(1)

I . . .

A vaccine effective in protecti . . es against infection by virulent strains of Streptococcus equi . g an immunizing dosage of an **attenuated Streptococcus equi** o . rendered avirulent while retaining its antigenicity through prolonged culturing in the presence of acriflavine hydrochlo .
<------User Break------>

d his

(FILE 'USPAT' ENTERED AT 16:19:37 ON 23 NOV 1998)

L1 0 S STREPTOCOCCUS EQUI AND AVIREULENT

L2 10 S STREPTOCOCCUS EQUI AND AVIRULENT

L3 3 S L2 AND ADJUVANT

L4 0 S TREPTOCOCCUS EQUI

L5 54 S STREPTOCOCCUS EQUI

L6 10 S L5 AND ADJUVANT

L3 ANSWER 14 OF 48 BIOTECHDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 1987-04225 BIOTECHDS
TI **Vaccine** for protection against **Streptococcus equi**;
containing **avirulent** mutant obtained from parent strain by mutagenesis
PA Cornell-Res.Found.
PI WO 8700436 29 Jan 1987
AI WO 1986-US1460 14 Jul 1986
PRAI US 1985-754613 12 Jul 1985
DT Patent
LA English
OS WPI: 1987-037174 [05]
AB A **vaccine** for protecting horses against **Streptococcus equi** (causing the disease strangles) comprises an **avirulent** strain of **S. equi** which stimulates an antibody response in the nasopharyngeal mucosa. The new strain is made by mutation of a virulent strain and retains a protein providing an M-protein fragment of mol.wt. 41,000. This fragment stimulates formation of IgG and IgA antibodies similar to those found in animals which have recovered from infection with virulent **S. equi**. The **avirulent** strain is non-encapsulated, and is especially **S. equi** 709-27 (ATCC 53186). The **vaccine** may be given intranasally or orally. 709-27 is developed from the highly virulent strain CF32 (ATCC 53185) by nitrosoguanidine mutagenesis followed by screening for loss of virulence and for ability to protect mice. The **vaccine** provides efficient protection without any side-effects in

Jenney

4748019

US6004802

L3 ANSWER 16 OF 48 CABA COPYRIGHT 1999 CABI
AN 86:39843 CABA
DN 862276553
TI The protective response of the horse to an **avirulent** strain of **Streptococcus equi**
AU Timoney, J. F.; Galan, J. E.; Y. Kimura [EDITOR]; others [EDITOR]
CS Coll. Vet. Med., Cornell Univ., Ithaca, NY 14853, USA.
SO Recent advances in streptococci and streptococcal diseases, (1985) pp. 294-295. Proceedings of the IXth Lancefield International Symposium on Streptococci and Streptococcal Diseases, Japan, September 1984. 7 ref. Publisher: Reedbooks Ltd. Chertsey
CY United Kingdom
DT Conference Article
LA English
AB **Avirulent** strain 709-27 of **S. equi**, developed as a **live vaccine** for nasal immunization against strangles, led to the production of IgA and IgG antibodies in the nasal mucosa, directed against a protein of 41 000 molecular weight.
Serum antibod

L3 ANSWER 6 OF 48 BIOTECHDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 1999-09279 BIOTECHDS
TI A **Streptococcus equi vaccine;**
live attenuated Streptococcus
equi vaccine, produced from **S.**
equi culture, used to **vaccinate** against strangles in horses
PA Akzo-Nobel
LO Arnheim, The Netherlands.
PI JP 11100329 13 Apr 1999
AI JP 1998-210514 27 Jul 1998
PRAI EP 1997-202925 24 Sep 1997; EP 1997-202365 29 Jul 1997
DT Patent
LA Japanese
OS WPI: 1999-296484 [25]
AB A **live, attenuated Streptococcus**
equi bacterium, especially **S. equi** TW928 (CBS813.95), used for the production of an optionally lyophilized **vaccine**, is claimed. The **vaccine** is used to prevent **S. equi** infection, following systemic administration, particularly by i.m. or s.m., particularly lip s.m. administration. The **vaccine** may optionally also include an adjuvant, an antigen, or another **attenuated** pathogen. The pathogen is preferably a Potomac fever agent, Rhodococcus equi, Clostridium tetani, Mycobacterium pseudomallei, Streptococcus zooepidemicus, vesicular stomatitis virus, Borna virus, horse influenza virus, African horse sickness virus, horse arteritis virus, equid herpes virus 1-4, infectious anemia virus, horse encephalomyelitis virus, or Japanese type-B encephalitis virus.
S. equi TW928 is **attenuated** by conventional techniques, and kept in a refrigerator, or a buffer containing glycerin at -70 deg. In an example, horse with no history of strangles were inoculated with the **vaccine**. Symptoms resulting from subsequent challenge with **S. equi** resulted in 98% decreased symptoms. (7pp)

EP 1997 - Issued EP 894500 3 Feb 99.

L3 ANSWER 3 OF 48 BIOSIS COPYRIGHT 1999 BIOSIS
AN 1995:484962 BIOSIS
DN PREV199598499262
TI An assessment of mucosal immunisation in protection against **Streptococcus equi** ('Strangles') infections in horses.
AU Wallace, Fiona J. (1); Emery, Julie D.; Cripps, Allan W.; Husband, Alan J.
CS (1) Dep. Pathol., Univ. Newcastle, Level 4, David Maddison Build., Royal Newcastle Hosp., Newcastle, N.S.W. 2300 Australia
SO Veterinary Immunology and Immunopathology, (1995) Vol. 48, No. 1-2, pp. 139-154.
ISSN: 0165-2427.
DT Article
LA English
AB The ability of mucosally administered antigen to provide protection against **Streptococcus equi** ('Strangles') infections in horses was examined. First, an enzyme linked immunosorbent assay (ELISA) was developed to detect the immune status of horses to **S. equi**. This assay was used to select Strangles-naive horses for the study and also to monitor their response to immunisation. Potential **vaccine** candidates were: (a) orally administered paraformaldehyde killed **S. equi**; (b) intraperitoneally (IP) administered paraformaldehyde killed **S. equi** in a non-inflammatory adjuvant; (c) orally administered **live avirulent S. equi**; (d) orally administered microencapsulated streptococcal M protein. The latter three preparations were first assessed in a rat model, using rate of lung bacterial clearance following intratracheal inoculation of **live** virulent bacteria as an indication of efficacy. Candidates (a) and (b) were then assessed in an equine model. IP immunisation of horses was shown to effectively induce production of specific antibody in mucosal and systemic sites. Four weeks after initial immunisation, horses were challenged intranasally with **live** virulent **S. equi**. Both groups of immunised horses demonstrated partial protection following **vaccination**. Of the IP immunised horses, only two out of four developed clinical signs of Strangles following **live** challenge. The orally immunised horses all developed submandibular abscesses containing **S. equi**. However, none of the immunised horses became as ill as the control horses in terms of fever, anorexia, loss of

L3 ANSWER 25 OF 48 LIFESCI COPYRIGHT 1999 CSA
AN 1999:66133 LIFESCI
TI **Streptococcus equi vaccine**
AU Hartford, O.A.; Foster, T.A.; Jacobs, A.R.H.
CS Provost Fellows & Scholars of the College of the Univ. of the Holy
SO (19990420) . US Patent 5895654; US CLASS: 424/237.1..
DT Patent
FS W2
LA English
SL English
AB The present invention relates to a **live attenuated** strain of the bacterium **Streptococcus equi**, a pathogen causing strangles in horses. The invention also relates to a **vaccine** against strangles, methods for the preparation of such a **vaccine** and to the use of the strain for the preparation of such a **v**

L3 ANSWER 24 OF 48 IFIPAT COPYRIGHT 1999 IFI
AN 2330060 IFIPAT;IFIUDB;IFICDB
TI PROTECTION OF EQUINES AGAINST **STREPTOCOCCUS EQUI**; BACTERIAL **VACCINE**; ADMINISTERING INTRANASALLY OR ORALLY TO HORSES
INF Timoney, John F, Lansing, NY
IN Timoney John F
PAF Cornell Research Foundation, Inc, Ithaca, NY
PA Cornell Research Foundation Inc (20656)
EXNAM Brown, Johnnie R
EXNAM Mohamed, Abdel A
AG Barnard, Ralph R
PI US 5183659 19930202
AI US 1988-207320 19880615
XPD 2 Feb 2010
RLI US 1985-754613 19850712 CONTINUATION ABANDONED
FI US 5183659 19930202
DT UTILITY
FS CHEMICAL
CLMN 10
GI 4 Drawing Sheet(s), 3 Figure(s).
AB A new bacterial **vaccine** to protect susceptible equine against **S. equi** which causes strangles. The **vaccine** stimulates a nasopharyngeal immune response in a susceptible equine through the presence of antibody activity in the nasopharyngeal mucus. The **vaccine** is a **S. equi** strain which contains an M protein fragment of 41,000 mw and is adapted for administration to equine either intranasally or orally as a **vaccine**. There is described a new strain of **S. equi** (709-27), a method of making and isolating useful **vaccine** strain of **S. equi** bacteria which stimulates an antibody response in the nasopharyngeal mucosa of the su

L3 ANSWER 13 OF 48 BIOTECHDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 1989-02559 BIOTECHDS
TI Horse strangles **vaccine**;
preparation by **attenuating Streptococcus equi** by culture in the presence of acriflavine hydrochloride
PA Coopers-Anim.Health
PI US 4788059 29 Nov 1988
AI US 1985-754909 15 Jul 1985
PRAI US 1985-754909 15 Jul 1985
DT Patent
LA English
OS WPI: 1988-360693 [50]
AB A **vaccine** effective in protecting horses against infection by virulent strains of **Streptococcus equi** is new.
S. equi is **attenuated** by prolonged (11 wk) culture in the presence of acriflavine hydrochloride. The culture medium may be Todd-Hewitt broth which preferably contains progressively increasing concentrations of acriflavine hydrochloride (2 ppm-16 ppm). Also new is a method of immunizing horses against virulent strains of **S. equi** which comprises inoculating the horses with **attenuated S. equi**, prepared using the new

T Money US
5,183659

L3 ANSWER 30 OF 48 TOXLIT
AN 1987:44829 TOXLIT
DN CA-106-162558X
TI **Vaccine** for the protection of equines against **streptococcus equi**.
AU Timoney JF
SO (1987). PCT Int. Appl. PATENT NO. 87 00436 01/29/87 (Cornell Research Foundation, Inc.).
CY United States
DT Patent
FS CA
LA English
OS CA 106:162558
EM 198706
AB **S. equi** 709-27, An equine human strain which contains an M protein fragment of mol. wt. 41,000, is used in a **live vaccine** to protect equines from strangles caused by **S. equi**. **S. equi** CF32 was subjected to nitrosoguanidine mutagenesis and nonencapsulated colonies were screened for loss of virulence in mice, for protection of horses, and by immunoblotting for formation of the 41,000-dalton fragment of M protein. IgA and IgG antibodies in the nasopharyngeal mucus of **vaccinated** ponies were directed mainly against this M protein fragment, whereas serum an